Results 181 to 190 of about 409,120 (302)

Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores. [PDF]

J Pers Med
Costantino J, Ballatore F, Porcelli D, Romani B, Campoli M, Zuccaro LM, Marchionni G, Alfarano M, Costantino S, Chimenti C.   +9 more
europepmc   +1 more source

Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Rare but severe adverse events (AEs) associated with mRNA‐lipid nanoparticle (LNP) COVID‐19 vaccines, such as Comirnaty, include anaphylaxis and inflammatory organ disorders, but their underlying mechanisms are poorly understood. We aimed to develop an animal model to study these phenomena.
László Dézsi, Gábor Kökény, Gábor Szénási, Csaba Révész, Tamás Mészáros, Bálint A. Barta, Réka Facsko, Anna Szilasi, Tamás Bakos, Gergely T. Kozma, Attila B. Dobos, Béla Merkely, Tamás Radovits, János Szebeni   +13 more
wiley   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

British Journal of Pharmacology, EarlyView.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam, James Harris, Jürgen Bernhagen, Antony Vinh, Katrina M. Mirabito Colafella   +4 more
wiley   +1 more source

Population-based screening for conditions associated with juvenile sudden cardiac death: a systematic review and meta-analysis. [PDF]

Eur Heart J Qual Care Clin Outcomes
Bonanni F, Capodici A, Gentile F, Moschetti F, Passino C, Di Paolo M, Olivotto I, Emdin M, Giannoni A.   +8 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Marathon-associated sudden cardiac death: a mini review of risk perception, pathophysiological mechanisms, and prevention strategies. [PDF]

Front Cardiovasc Med
Zhang X, Li S, Mai Y, Chen H, Wu H, Li C, Zhao L, Peng J.   +7 more
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

From Diagnostic Mimicry to Diagnostic Clarity: Reframing Idiopathic Ventricular Fibrillation After Aborted Sudden Cardiac Death. [PDF]

JACC Case Rep
El-Battrawy I, Akin I, Khan M, van Heerebeek L, Hamdani N.   +4 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source